FDA Approves SELUTION SLR Drug-Eluting Balloon for Coronary In-Stent Restenosis
The U.S. Food and Drug Administration has approved the SELUTION SLR Drug-Eluting Balloon for treating coronary in-stent restenosis, marking the first sirolimus-based drug-coated balloon authorized in the U.S. This approval follows the SELUTION4ISR trial involving over 400 patients across multiple countries, demonstrating non-inferiority to standard treatments. Developed over more than a decade and commercialized by Cordis after acquiring MedAlliance, the device offers a new option beyond the previously available paclitaxel-based balloons. Cordis is also conducting further trials for additional indications.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (82/100). Lens Score 43/100.
Outlets measured: businessstandard, thetribune. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (78–85/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thetribune broke this story on 25 Sept, 10:06 am. Other outlets followed.